TABLE 3 

VirCapSeq-VERT performance compared to conventional enrichment procedures

Treatment (preparation)aVirus load (copies)b (HHV/FLUAV/EV)No. of readsNo. of reads (total/normalizedd)
ViralMapped to virus
HHV-1FLUAVEV-D68
DNase (conventional)6 × 102/ND/9 × 10220,449,329219/10759/29c6/3154/75
RiboZero (conventional)2 × 103/8 × 102/2 × 10382,866,2694,251/5132,951/35639/51,261/152
DNase/RiboZero (conventional)ND/ND/2 × 10368,239,8343,927/5766/0.9c3/0.43,918/575
None (conventional)2 × 104/3 × 104/2 × 104121,961,8814,562/3742,569/21165/51,928/158
None (VirCapSeq-VERT)2 × 104/2 × 104/2 × 104128,764,1302,773,382/215,325713,557/55,400572,169/44,4231,487,656/115,501
None (VirCapSeq-VERT)e9 × 102/8 × 102/9 × 10264,989,06086,943/13,37621,631/3,32819,255/2,96246,057/7,086
  • a Human blood was spiked with live virus stocks derived from tissue culture to result in approximately 104 copies of herpes simplex virus 1 (HHV-1), influenza A virus (FLUAV), and enterovirus D68 (EV-D68) per 250 ng extracted blood NA. The sample was divided into equivalent aliquots to be processed with the indicated treatment prior to RT reaction and subjected to either conventional sequence library preparation or VirCapSeq-VERT.

  • b Determined by qPCR of double-stranded cDNA/DNA used for sequence library construction.

  • c HHV-1 detection was impaired due to DNase.

  • d Normalized to 10,000,000 total reads.

  • e Prepared with additional dilution of the sample in a blood background.